Literature DB >> 9700592

Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations.

V Leuzzi1, S Rinalduzzi, F Chiarotti, P Garzia, G Trasimeni, N Accornero.   

Abstract

During detailed visual function testing, pattern-reversal visual evoked potentials (VEP), generated by different spatial frequencies (3 c/d, 1 c/d and 0.6 c/d) and visual contrasts (100% and 10%) were recorded in 21 adolescent and young adult phenylketonuric (PKU) patients (11 females and 10 males; mean age 14.8 years, range 9-22.8) on and off diet. In 14 of the 21 patients, disease had been detected at neonatal screening and in 7 later. Ten age-matched healthy subjects acted as controls. Recordings in more than 40% of eyes in the whole group and 30% of eyes in the screening subgroup showed a prolonged P100 latency. All visual pattern stimuli elicited a significantly longer P100 latency in PKU patients than in controls. VEP latencies to 3 c/d, 1 c/d and 1 c/d with 10% contrast--but not to 0.6 c/d--were longer in patients off diet than in patients on diet. No differences were found between VEP latencies in early- and later-detected subjects. To study the link between biochemical variables and VEP latencies, we envisaged either a linear relationship between recent exposure to phenylalanine (Phe) and VEP abnormalities or a threshold model considering phenylalanine (Phe) concentrations among the factors influencing VEP latencies. The correlation analysis detected an association between plasma Phe concentrations and abnormal VEP latencies, predicting that plasma Phe concentrations > 901 mumol/L would prolong VEP latencies to 1 c/d; concentrations > 879 mumol/L would prolong latencies to 3 c/d; and concentrations > 898 mumol/L would prolong latencies to 1 c/d with 10% contrast.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700592     DOI: 10.1023/a:1005346422918

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  39 in total

1.  Abnormalities in color vision and contrast sensitivity in Parkinson's disease.

Authors:  M J Price; R G Feldman; D Adelberg; H Kayne
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

2.  Effect of levodopa treatment on contrast sensitivity in Parkinson's disease.

Authors:  C Bulens; J D Meerwaldt; G J Van der Wildt; J B Van Deursen
Journal:  Ann Neurol       Date:  1987-09       Impact factor: 10.422

3.  Late onset phenylalanine intoxication.

Authors:  L I Woolf
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

4.  Dopaminergic drugs improve human visual contrast sensitivity.

Authors:  L Domenici; C Trimarchi; M Piccolino; A Fiorentini; L Maffei
Journal:  Hum Neurobiol       Date:  1985

5.  Evoked potentials and electroencephalography in adolescents with phenylketonuria.

Authors:  R Korinthenberg; K Ullrich; F Füllenkemper
Journal:  Neuropediatrics       Date:  1988-11       Impact factor: 1.947

6.  Dopaminergic deficiency and delayed visual evoked potentials in humans.

Authors:  I Bodis-Wollner; M D Yahr; L Mylin; J Thornton
Journal:  Ann Neurol       Date:  1982-05       Impact factor: 10.422

7.  Acute effects of levodopa plus carbidopa on evoked potentials in Parkinson's disease.

Authors:  V Cosi; A Romani; R Callieco; F Zerbi
Journal:  Boll Soc Ital Biol Sper       Date:  1984-03-30

8.  Evolution of daytime quiet sleep components in early treated phenylketonuric infants.

Authors:  G F De Giorgis; E Nonnis; F Crocioni; P Gregori; M P Rosini; V Leuzzi; A Loizzo
Journal:  Brain Dev       Date:  1996 May-Jun       Impact factor: 1.961

9.  Color VEPs in Parkinson's disease.

Authors:  L Barbato; S Rinalduzzi; M Laurenti; S Ruggieri; N Accornero
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1994-03

10.  Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ.

Authors:  S J Jones; G Turano; A Kriss; F Shawkat; B Kendall; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-09       Impact factor: 10.154

View more
  7 in total

Review 1.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

2.  Executive function impairment in early-treated PKU subjects with normal mental development.

Authors:  V Leuzzi; M Pansini; E Sechi; F Chiarotti; Cl Carducci; G Levi; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

3.  Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis.

Authors:  Christopher J Fonnesbeck; Melissa L McPheeters; Shanthi Krishnaswami; Mary Louise Lindegren; Tyler Reimschisel
Journal:  J Inherit Metab Dis       Date:  2012-11-30       Impact factor: 4.982

Review 4.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

5.  Phenylketonuria: nutritional advances and challenges.

Authors:  Marcello Giovannini; Elvira Verduci; Elisabetta Salvatici; Sabrina Paci; Enrica Riva
Journal:  Nutr Metab (Lond)       Date:  2012-02-03       Impact factor: 4.169

6.  Pre-attentive processing in children with early and continuously-treated PKU. Effects of concurrent Phe level and lifetime dietary control.

Authors:  Leo M J de Sonneville; Stephan C J Huijbregts; Robert Licht; Joseph A Sergeant; Francjan J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2011-05-04       Impact factor: 4.982

7.  Age-related psychophysiological vulnerability to phenylalanine in phenylketonuria.

Authors:  Vincenzo Leuzzi; Daniela Mannarelli; Filippo Manti; Caterina Pauletti; Nicoletta Locuratolo; Carla Carducci; Claudia Carducci; Nicola Vanacore; Francesco Fattapposta
Journal:  Front Pediatr       Date:  2014-06-23       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.